TRPV1 receptor blockade is ineffective in different in vivo models of migraine

Cephalalgia

Volumn 31, Issue 2, 2011, Pages 172-180

  Summ, Oliver ^a   Holland, Philip R ^b   Akerman, Simon ^a   Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

migraine; Trigeminal nucleus; TRPV1 receptor

Indexed keywords

A 993610; CAPSAICIN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MALE; MIGRAINE; MIGRAINE AURA; NONHUMAN; RAT; RECEPTOR BLOCKING; SPREADING CORTICAL DEPRESSION; VASODILATATION;

ACUTE DISEASE; ANIMALS; CAPSAICIN; CORTICAL SPREADING DEPRESSION; DISEASE MODELS, ANIMAL; MALE; MIGRAINE WITH AURA; NEEDLESTICK INJURIES; NERVE FIBERS, UNMYELINATED; RATS; RATS, SPRAGUE-DAWLEY; SENSORY SYSTEM AGENTS; TRIGEMINAL NERVE; TRPV CATION CHANNELS; VASODILATION;

EID: 79751493603     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410375626     Document Type: Article

References (53)

1. Menken M., Munsat TL, Toole JF The global burden of disease study-implications for neurology. Arch Neurol 2000 ; 57: 418-420. (Pubitemid 30140537)
2. Lipton RB, Stewart WF, Diamond S., Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 ; 41: 646-657. (Pubitemid 32777747)
3. Stewart WF, Ricci JA, Chee E., Morganstein D., Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003 ; 290: 2443-2454. (Pubitemid 37430544)
4. Andlin-Sobocki P., Jonsson B., Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005 ; 12: 1-27.
5. Goadsby PJ, Lipton RB, Ferrari MD Migraine-current understanding and treatment. New Engl J Med 2002 ; 346: 257-270.
6. Goadsby PJ The pharmacology of headache. Prog Neurobiol 2000 ; 62: 509-525. (Pubitemid 30408159)
7. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 ; 358: 1668-1675. (Pubitemid 33124324)
8. Dodick D., Lipton RB, Martin V., et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004 ; 44: 414-425. (Pubitemid 38685549)
9. Goadsby PJ Emerging therapies for migraine. Nature Clin Pract Neurol 2007 ; 3: 610-619. (Pubitemid 350048227)
10. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008 ; 372: 2115-2123.
11. Tominaga M., Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998 ; 21: 531-543. (Pubitemid 28475505)
12. Tominaga M., Caterina MJ Thermosensation and pain. J Neurobiol 2004 ; 61: 3-12. (Pubitemid 39302620)
13. Nagy I., Santha P., Jancso G., Urban L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004 ; 500: 351-369. (Pubitemid 39304020)
14. Cromer BA, McIntyre P. Painful toxins acting at TRPV1. Toxicon 2008 ; 51: 163-173.
15. Nicoletti P., Trevisani M., Manconi M., et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 2008 ; 28: 9-17. (Pubitemid 350212646)
16. Meng J., Ovsepian SV, Wang J., et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009 ; 29: 4981-4992.
17. Wolff HG Headache and other head pain. New York: Oxford University Press, 1948.
18. Bergerot A., Holland PR, Akerman S., et al. Animal models of migraine. Looking at the component parts of a complex disorder. Eur JNeurosci 2006 ; 24: 1517-1534. (Pubitemid 44429881)
19. Goadsby PJ, Hoskin KL Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996 ; 67: 355-359. (Pubitemid 26375351)
20. Shepheard SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997 ; 36: 525-533.
21. Headache Classification Committee of the International Headache Society. International classification of headache disorders. 2nd ed. Cephalalgia 2004 ; 24: 1-160.
22. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994 ; 117: 199-210. (Pubitemid 24103394)
23. Summ O., Holland PR, Akerman S., Goadsby PJ The TRPV1 receptor antagonist A993610 shows no effect on trigeminal firing recorded in the trigeminocervical complex. Cephalalgia 2009 ; 29: 109.
24. Summ O., Akerman S., Holland PR, Goadsby PJ The TRPV1 receptor antagonist, A-993610, shows no effect on neurogenic dural dilation but is able to block capsaicin-induced dilation. Cephalalgia 2009 ; 29: 136.
25. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983 ; 16: 109-110. (Pubitemid 13058546)
26. Akerman S., Williamson D., Goadsby PJ Voltage-dependent calcium channels are involved in neurogenic dural vasodilation via a pre-synaptic transmitter release mechanism. Br J Pharmacol 2003 ; 140: 558-566. (Pubitemid 37330500)
27. Honore P., Chandran P., Hernandez G., et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009 ; 142: 27-35.
28. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. London: Academic Press, 1998.
29. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 1997 ; 17: 518-524. (Pubitemid 27248489)
30. Akerman S., Williamson DJ, Kaube H., Goadsby PJ Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002 ; 137: 62-68. (Pubitemid 34983464)
31. Akerman S., Kaube H., Goadsby PJ Vanilloid type 1 receptors (VR1) on trigeminal nerve fibres play a minor role in causing dural vessel dilation via the trigeminovascular system. Br J Pharmacol 2003 ; 140: 718-724. (Pubitemid 37386436)
32. Hou M., Uddman R., Tajti J., Kanje M., Edvinsson L. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett 2002 ; 330: 223-226. (Pubitemid 35254040)
33. Shimizu T., Toriumi H., Sato H., et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res 2007 ; 1173: 84-91. (Pubitemid 47445453)
34. Acs G., Palkovits M., Blumberg PM Specific binding of [3H]resiniferatoxin by human and rat preoptic area, locus ceruleus, medial hypothalamus, reticular formation and ventral thalamus membrane preparations. Life Sci 1996 ; 59: 1899-1908. (Pubitemid 26381154)
35. Mezey E., Toth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000 ; 97: 3655-3660. (Pubitemid 30183358)
36. Roberts JC, Davis JB, Benham CD [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 2004 ; 995: 176-183. (Pubitemid 37522018)
37. Davies AJ, North RA Electrophysiological and morphological properties of neurons in the substantia gelatinosa of the mouse trigeminal subnucleus caudalis. Pain 2009 ; 146: 214-221.
38. Sasamura T., Sasaki M., Tohda C., Kuraishi Y. Existence of capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuroreport 1998 ; 9: 2045-2048. (Pubitemid 28300564)
39. McGaraughty S., Chu KL, Bitner RS, et al. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 2003 ; 90: 2702-2710. (Pubitemid 37266534)
40. Goadsby PJ, Charbit AR, Andreou AP, Akerman S., Holland PR Neurobiology of migraine. Neuroscience 2009 ; 161: 327-341.
41. Akerman S., Goadsby PJ Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 2005 ; 16: 1383-1387. (Pubitemid 41225215)
42. Ayata C., Jin H., Kudo C., Dalkara T., Moskowitz MA Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006 ; 59: 652-661.
43. Lappin SC, Randall AD, Gunthorpe MJ, Morisset V. TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol 2006 ; 540: 73-81. (Pubitemid 44177497)
44. Xing J., Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 2007 ; 97: 503-511. (Pubitemid 46143373)
45. Kim H., Cui L., Kim J., Kim SJ Transient receptor potential vanilloid type 1 receptor regulates glutamatergic synaptic inputs to the spinothalamic tract neurons of the spinal cord deep dorsal horn. Neuroscience 2009 ; 160: 508-516.
46. Gavva NR, Tamir R., Klionsky L., et al. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol Pharmacol 2005 ; 68: 1524-1533. (Pubitemid 41654336)
47. Lehto SG, Tamir R., Deng H., et al. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008 ; 326: 218-229. (Pubitemid 351872146)
48. Walker KM, Urban L., Medhurst SJ, et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003 ; 304: 56-62. (Pubitemid 36008912)
49. Gavva NR, Tamir R., Qu Y., et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2, 3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005 ; 313: 474-484. (Pubitemid 40411374)
50. Jhaveri MD, Elmes SJ, Kendall DA, Chapman V. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naive, carrageenan-inflamed and neuropathic rats. Eur J Neurosci 2005 ; 22: 361-370. (Pubitemid 41097609)
51. Lambert GA, Davis JB, Appleby JM, et al. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 2009 ; 380: 311-325.
52. Goadsby PJ, Knight YE Inhibition of trigeminal neurons after intravenous administration of naratriptan through an action at the serotonin (5HT1B/1D) receptors. Br J Pharmacol 1997 ; 122: 918-922. (Pubitemid 27460175)
53. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997 ; 328: 61-64. (Pubitemid 27241396)